Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 1
1964 1
1982 2
1985 1
1986 2
1987 5
1988 3
1991 1
1994 1
1995 1
1997 1
1998 1
2000 1
2002 2
2004 6
2005 15
2006 13
2007 6
2008 8
2009 9
2010 23
2011 21
2012 15
2013 19
2014 16
2015 15
2016 12
2017 7
2018 12
2019 15
2020 14
2021 16
2022 17
2023 22
2024 35
2025 33

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

330 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, Diva UA, Floege J, Gesualdo L, Inrig JK, Kohan DE, Komers R, Kooienga LA, Lafayette R, Maes B, Małecki R, Mercer A, Noronha IL, Oh SW, Peh CA, Praga M, Preciado P, Radhakrishnan J, Rheault MN, Rote WE, Tang SCW, Tesar V, Trachtman H, Trimarchi H, Tumlin JA, Wong MG, Perkovic V; DUPRO steering committee and PROTECT Investigators. Rovin BH, et al. Lancet. 2023 Dec 2;402(10417):2077-2090. doi: 10.1016/S0140-6736(23)02302-4. Epub 2023 Nov 3. Lancet. 2023. PMID: 37931634 Clinical Trial.
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial.
Heerspink HJL, Radhakrishnan J, Alpers CE, Barratt J, Bieler S, Diva U, Inrig J, Komers R, Mercer A, Noronha IL, Rheault MN, Rote W, Rovin B, Trachtman H, Trimarchi H, Wong MG, Perkovic V; PROTECT Investigators. Heerspink HJL, et al. Lancet. 2023 May 13;401(10388):1584-1594. doi: 10.1016/S0140-6736(23)00569-X. Epub 2023 Apr 1. Lancet. 2023. PMID: 37015244 Clinical Trial.
Risk of Uveitis among E-Cigarette Users: A Multi-institutional TriNetX Study.
Hsu AY, Wang YH, Hsia NY, Lai CT, Kuo HT, Wu BQ, Lin CJ, Chiang CC, Shao YC, Chen HS, Tsai YY, Wei JC. Hsu AY, et al. Among authors: kuo ht. Ophthalmology. 2025 Mar;132(3):370-373. doi: 10.1016/j.ophtha.2024.11.008. Epub 2024 Nov 12. Ophthalmology. 2025. PMID: 39536980 No abstract available.
Cataract Development Among Pediatric Patients With Uveitis.
Hsu AY, Kuo HT, Lin CJ, Hsia NY, Kuo SC, Wei CC, Lai CT, Chen HS, Wang YH, Wei JC, Tsai YY. Hsu AY, et al. Among authors: kuo ht. JAMA Netw Open. 2024 Jul 1;7(7):e2419366. doi: 10.1001/jamanetworkopen.2024.19366. JAMA Netw Open. 2024. PMID: 38949811 Free PMC article.
330 results